KF1601, a dual inhibitor of BCR::ABL1 and FLT3, overcomes drug resistance in FLT3+ blast phase chronic myeloid leukemia
Kwon, H.-J., Shin, J.E., Khan, A., Park, S.Y., Kim, J., Lee, J.-Y., Lee, D., Lee, S., Im, C.Y., Moon, H., Han, Y.R., Tamai, M., Akahane, K., Inukai, T., Lee, W., Kim, H., 김홍남, Ahn, S.-M., 박현우, Kim, D.-W.
Molecular Cancer, 202504